Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation.
IMRT
T1 glottic squamous cell carcinoma
larynx cancer
oncologic outcomes
radiation therapy
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
20
06
2018
revised:
19
01
2019
accepted:
28
01
2019
pubmed:
14
2
2019
medline:
3
7
2020
entrez:
14
2
2019
Statut:
ppublish
Résumé
We aim to report oncologic outcomes after conventional radiotherapy (ConRT) using opposed lateral beams and intensity-modulated radiation therapy (IMRT) for tumor (T)1 nodal (N)0 T1 N0 glottic squamous cell carcinoma. Retrospective case-control study. We retrospectively reviewed demographic, disease, and treatment characteristics for patients treated at our institution during 2000 to 2013. One hundred fifty-three patients (71%) were treated using ConRT and 62 (29%) using IMRT. The median follow-up for all patients was 68 months. There was no statistically significant difference in 5-year local control between patients with T1a versus T1b disease (94% vs. 89%, respectively, P = 0.5). Three-year locoregional control for patients treated with ConRT was 94% compared to 97% with IMRT (P = 0.4). Three-year overall survival (OS) for patients treated with ConRT was 92.5% compared with 100% with IMRT (P = 0.1). Twelve of 14 patients with local recurrence underwent salvage surgery with 5-year ultimate locoregional control of 98.5% and 97.1% in the ConRT and IMRT cohorts, respectively (P = 0.7). Multivariate analysis showed age < 60 years (P < 0.0001) and pretreatment Eastern Cooperative Oncology Group performance status <2 (P = 0.0022) to be independent correlates of improved OS. Postradiation cerebrovascular events were in four patients in the ConRT cohort (3%), whereas no patients in the IMRT cohort suffered any events. Because the oncologic outcomes for patients treated with IMRT were excellent and IMRT allows for carotid sparing, we have transitioned to IMRT as our standard for most patients with T1 glottic cancer. 3b Laryngoscope, 130:146-153, 2020.
Identifiants
pubmed: 30756394
doi: 10.1002/lary.27873
pmc: PMC6895404
mid: NIHMS1047882
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
146-153Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE025248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214825
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218148
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA225190
Pays : United States
Informations de copyright
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.
Références
J Appl Clin Med Phys. 2014 Jan 08;16(1):5108
pubmed: 25679151
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1361-7
pubmed: 16169673
Kulak Burun Bogaz Ihtis Derg. 2012 Sep-Oct;22(5):267-74
pubmed: 22991987
Radiat Oncol. 2010 Aug 26;5:74
pubmed: 20796303
Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e180-6
pubmed: 22862908
Clin Transl Oncol. 2013 Nov;15(11):925-31
pubmed: 23519536
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):255-60
pubmed: 25304787
Head Neck. 2012 Jul;34(7):1009-14
pubmed: 22052787
Laryngorhinootologie. 2005 Feb;84(2):96-100
pubmed: 15712044
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):989-97
pubmed: 21300449
J Clin Oncol. 2002 Jan 1;20(1):282-8
pubmed: 11773180
Radiother Oncol. 2013 Jan;106(1):69-73
pubmed: 23324589
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1380-5
pubmed: 19942356
Strahlenther Onkol. 2010 Nov;186(11):607-13
pubmed: 21069268
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):2-3
pubmed: 17448864
Laryngoscope. 2002 Oct;112(10):1883-7
pubmed: 12368635
Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):589-96
pubmed: 27681754
Radiat Oncol J. 2016 Mar;34(1):26-33
pubmed: 27104164
Head Neck. 2011 Apr;33(4):581-6
pubmed: 20848441
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):455-61
pubmed: 19679406
Otolaryngol Head Neck Surg. 2017 Apr;156(4):677-682
pubmed: 28322111
Jpn J Clin Oncol. 2011 Jan;41(1):103-9
pubmed: 20696816
Am J Clin Oncol. 2013 Dec;36(6):580-3
pubmed: 22868239
Br J Radiol. 2010 Jul;83(991):554-68
pubmed: 20603408
Clin Exp Otorhinolaryngol. 2012 Jun;5(2):94-100
pubmed: 22737290
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):532-540
pubmed: 28258898
Laryngoscope. 2009 Aug;119(8):1531-7
pubmed: 19489068
Head Neck Oncol. 2012 May 18;4:23
pubmed: 22607730
Radiat Oncol. 2012 Nov 19;7:193
pubmed: 23164282
Am J Clin Oncol. 2010 Dec;33(6):587-90
pubmed: 20051812
Oral Oncol. 2015 Jul;51(7):716-23
pubmed: 25958831
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):461-6
pubmed: 20153124
Br J Radiol. 2014 Jun;87(1038):20130754
pubmed: 24628251
Radiat Oncol. 2015 Sep 23;10:203
pubmed: 26395876
J Clin Oncol. 2008 Nov 1;26(31):5119-25
pubmed: 18725647
Cancer Res Treat. 2015 Oct;47(4):862-70
pubmed: 25687859
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):290-6
pubmed: 23906930
Tumori. 2010 Jul-Aug;96(4):577-81
pubmed: 20968137